Simcere, Merck deal

The partners amended a 2011 JV under which the companies were commercializing a combined portfolio of off-patent cardiovascular and metabolic drugs. In a joint statement,

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE